The 2022 ACR Awards of Distinction

“I plan to remain engaged in scientific discovery that I hope can transform care for patients with lupus, in advocating for women in science and medicine and beyond, and in trying to address inequities in healthcare,” Dr. Diamond says.

Distinguished Service Award

The ACR Distinguished Service Award was presented to Daniel J. Lovell, MD, MPH, and James T. Rosenbaum, MD, MACR, for outstanding and sustained service to the ACR. 

Daniel J. Lovell, MD, MPH, serves as the Joseph Levinson Professor of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati School of Medicine.

“Receiving this Distinguished Service Award from the ACR is really moving [because] the recognition comes from colleagues with whom I have worked for decades and whom I respect highly,” says Dr. Lovell. “My career has been focused on serving children with rheumatic diseases and the ACR has provided me many avenues to serve that help children.”

Dr. Lovell attended medical school at the University of Kansas School of Medicine, Kansas City, and completed a pediatric residency at the Children’s Mercy Hospital, Kansas City, Mo. He received a Master in Public Health from the University of Texas School of Public Health, Houston, while completing a pediatric rheumatology fellowship at Baylor College of Medicine, Houston, under the directorship of Earl Brewer, MD. Since completing fellowship training, he has been a faculty member, for 38 years, of the Division of Rheumatology at Cincinnati Children’s Hospital Medical Center.

The central focus of Dr. Lovell’s career is the longitudinal care of children and young adults with rheumatic and other chronic musculoskeletal conditions. His research has focused on the development of outcome measures for pediatric rheumatic diseases, validated measures for use in clinical trials and performance of multicenter, randomized controlled trials in children with juvenile idiopathic arthritis (JIA). He has served in a leadership role on most of the trials of biologics and a Janus kinase inhibitor in children with polyarticular JIA and biologics for systemic JIA. He has had continuous National Institutes of Health (NIH) funding for over 25 years.

Dr. Lovell served as the chair of the Pediatric Rheumatology Collaborative Study Group (PRCSG) for 30 years (1992–2022) and was a founding member of the Childhood Arthritis and Rheumatology Research Alliance (CARRA), serving on the Steering Committee for the organization’s first six years. 

He has served as chair of the ACR Drug Safety Committee, a member of the ACR Quality of Care Committee (previously the Quality Measures Committee) and on the steering committees for all three ACR JIA guideline committees. He has served on the U.S. Food & Drug Administration Arthritis Advisory Committee, the NIH and Arthritis Foundation Study Sections, and was a founding member of the Pediatric Rheumatology Section of the ACR.